Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura.

Trial Profile

Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2014

At a glance

  • Drugs NXN 188 (Primary)
  • Indications Migraine without aura
  • Focus Therapeutic Use
  • Sponsors NeurAxon
  • Most Recent Events

    • 01 Nov 2010 Primary endpoint 'Headache severity' has not been met.
    • 01 Nov 2010 Results were reported in a NeuAxon media release.
    • 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top